argenx SE (STU:1AE)
€ 553.6 6 (1.1%) Market Cap: 33.43 Bil Enterprise Value: 30.56 Bil PE Ratio: 0 PB Ratio: 8.44 GF Score: 82/100

Q1 2022 argenx SE Earnings Call Transcript

May 05, 2022 / 12:30PM GMT
Release Date Price: €287 (+2.94%)
Operator

Good morning. My name is Adam, and I will be your conference operator today. At this time, I would like to welcome everyone to today's call. (Operator Instructions) I'd like to introduce Beth DelGiacco, Vice President of Corporate Communications and Investor Relations. You may now begin your conference.

Beth DelGiacco
argenx SE - VP and Global Head of Corporate Communications & IR

Thank you, operator. Two press releases were issued earlier today, one which summarizes the positive results from our Phase III ADVANCE trial and the other which outlines our first quarter 2022 financial results and business updates. These can be found on our website along with the presentation for today's webcast. Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones. Actual results may differ materially from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot